Company
Arovella Therapeutics Ltd
ASX:ALA
Arovella Therapeutics Ltd is a biotechnology company focused on developing its unique iNKT cell therapy platform to treat cancer. The company expects ALA-101 (CAR19-iNKT) cells to be effective against blood cancers that naturally produce CD19.
83 stories
Arovella Therapeutics secures European patent for iNKT cell therapy platform
The patent application covers the manufacture of CAR-iNKT cells and is expected to proceed to grant in early 2023, with a maximum term expiring on February 28, 2039.
Arovella Therapeutics' strategic refocus on iNKT platform a sensible move: Edison Investment Research
Arovella’s decision may have been bolstered by the recently-announced collaboration with Imugene, which could potentially expand the platform’s utility into the multi-fold solid tumour space, the research firm said.
Arovella Therapeutics shifts focus to iNKT cell therapy platform; to close Perth OroMist R&D facility
The company intends to focus entirely on the development of its iNKT cell therapy platform, which has significant potential to generate allogeneic cell therapies that target blood cancers and solid tumours.
Arovella Therapeutics joins forces with Imugene in pre-clinical trial to treat solid tumours; shares jump
"We are excited to collaborate with Imugene to evaluate the potential of our iNKT product in combination with their onCARlytics product for treatment of solid tumours. Imugene's onCARlytics is one of the most promising products to be develo
Arovella Therapeutics maintains $30.5 million valuation from Edison Investment Research
The company recently launched its most advanced clinical asset, ZolpiMist to the Australian market.
Arovella Therapeutics bolsters management experience with appointment of non-executive director
“Gary has an incredible breadth of experience across the drug development continuum, from early-stage research to the creation of significant value-creating partnerships. We welcome Gary’s experience across numerous domains, and we are deli
Arovella Therapeutics' oral-spray insomnia treatment commercially launched in Australia by partner STADA
CEO and MD Dr Michael Baker welcomed the early milestone: “We see ZolpiMist as an important product to assist with sleep, particularly with the lingering effects of the COVID-19 pandemic."
Arovella Therapeutics adopts World Economic Forum framework for ESG reporting
“We greatly value ESG considerations as they enable us to better identify material risks and growth potential, leading to better-informed decisions and business outcomes. Equally, our commitment to ESG creates a consistent and measurable ap
Arovella Therapeutics unveils board changes
Arovella is a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system.
Arovella Therapeutics readies to manufacture iNKT cell therapy for clinical trials
“We see the development of an off-the-shelf product as an essential step forward for the cell therapy field,” says CEO & MD.
Arovella Therapeutics attracts increased valuation from Edison Group
The company’s total valuation has been increased to A$30.5 million or A$0.05 per basic share from A$25 million reflecting higher cash levels due to the recent capital raising activity.
Arovella Therapeutics secures US patent for cancer treatment Anagrelide
“Receiving the notice that this patent will proceed to grant is incredibly important for the commercial prospects of the technology. The US is a key market for a product of this nature, and we now have patents covering a substantial proport
Arovella Therapeutics share purchase plan is “inundated”; closes early and oversubscribed
The company has been conducting an offer of new shares by way of an underwritten SPP to raise a target amount of $1.5 million from existing Australian and New Zealand shareholders.
Arovella Therapeutics sees $0.11 valuation in new coverage from Diamond Equity Research
The firm reached its valuation in view of the biotech’s forays into cancer-treating immunotherapies following a former life as an oro-mucosal administration platform.
Arovella Therapeutics appoints senior preclinical development and translational medicine expert to strengthen team
“Dr Bharathan is an exceptionally talented immunologist, with many years of experience taking cell therapies from preclinical stages and into and through clinical trials, particularly allogenic therapies."
Arovella Therapeutics Ltd raises $4.5 million to progress therapies to treat human diseases
“This capital raising is a significant step towards bringing Arovella’s highly prospective cell therapy pipeline to the clinic and, ultimately, to market. This is a testament to the hard work of Michael and the team in recent years,” says C
Arovella Therapeutics outlook brightens with rights to monoclonal antibody targeting cancer, says Edison
Edison notes that it has not yet included the company's two CAR-iNKT programs in its valuation, hinting at the prospect of a revised valuation when the products hit the clinic.
Arovella Therapeutics licenses monoclonal antibody/CAR oncology treatment, shares up
“The data that we have seen for the DKK1-CAR is compelling. We see a lot of promise in combining DKK1-CAR with our iNKT cell therapy platform and expect synergistic effects for the treatment of certain cancers," says MD.
Arovella Therapeutics receives $524,000 R&D Tax Incentive refund
The refund recognises the research and development activities undertaken by the biotechnology company during the 2021 financial year.
Arovella Therapeutics strengthens drug development pipeline expertise by appointing life-sciences veteran as director
“Liz is one of the rare individuals in the industry whose career spans the continuum of drug development, from leading early-stage research through to the commercialisation of final products. This is an exciting time in Arovella’s evolution
Applabs Technologies selling part of Fee for Service division
The sale of assets to Dapper Apps Pty Ltd will allow the company to focus on maturing its strategic investments. Operational and corporate overheads are also expected to be reduced to about $700,000 per annum from 1st July 2015.